



# Achieving control in Crohn's disease: today and tomorrow

SUNDAY 15 OCTOBER 2023 | 12:00-13:00 CEST | ROOM A1 | ALSO STREAMED LIVE

## How far have we come in Crohn's disease management?



### JEAN-FREDERIC COLOMBEL (CHAIR)

The Susan and Leonard Feinstein  
Inflammatory Bowel Disease Clinical Center,  
Icahn School of Medicine at Mount Sinai,  
New York, NY, USA

Jean-Frederic Colombel is the Director of both the Susan and Leonard Feinstein Inflammatory Bowel Disease (IBD) Clinical Center and the Leona M. and Harry B. Helmsley Charitable Trust IBD Research Center at the Icahn School of Medicine at Mount Sinai, New York, USA.

Since 1984, his research has focused on IBD, and thanks to the development of multiple local, national, and international collaborations, he has been able to contribute to important advances in the pathophysiology of the disease. For the past 20 years, Dr. Colombel has worked on multiple clinical trials to develop new IBD treatments, especially biologics, or to improve therapeutic strategies. One tangible record of his accomplishments has been the publication as primary author or co-author for more than 1,070 peer-reviewed papers with an H index of 185.

In 2009, Dr. Colombel was awarded the United European Gastroenterology Federation Research Prize. Later, he was awarded the Crohn's and Colitis Foundation Clinical Research Award in 2014, the Sherman Prize in 2018, and most recently, the Jacobi Medallion in 2022. Dr. Colombel has also been past president for the Group d'Étude Thérapeutique des Affections Inflammatoires de Tube Digestif (GETAID), the European Crohn's and Colitis Organisation, and has been past chair for the International Organization for Inflammatory Bowel Disease (IOIBD).

## Evolving treatment strategies and approaches: making disease modification a reality



### BRIAN BRESSLER

Department of Medicine,  
University of British Columbia,  
Vancouver, British Columbia, Canada

Brian Bressler is a Clinical Associate Professor at the University of British Columbia (BC), Vancouver, BC, Canada, where he directs the Advanced Inflammatory Bowel Disease (IBD) training program. He also works as a Staff Gastroenterologist at St Paul's Hospital in Vancouver.

Dr. Bressler is a recognized expert in IBD. His research interests focus on population-based studies, classical clinical epidemiology, and clinical trials in IBD; to date, he has authored or co-authored more than 50 IBD-related papers.

## Unlocking the future of Crohn's disease management



### MARIA T. ABREU

Crohn's & Colitis Center,  
University of Miami, Miller School  
of Medicine, Miami, FL, USA

Maria T. Abreu is a gastroenterologist specializing in inflammatory bowel disease. She is currently Director of the Crohn's and Colitis Center, Professor of Medicine and Professor of Microbiology and Immunology at the University of Miami Miller School of Medicine.

Dr Abreu has more than 20 years of leadership experience in basic, translational, and clinical research and mentoring. She has authored more than 200 peer-reviewed articles, books, chapters, and reviews.

Dr Abreu was elected to the American Society for Clinical Investigation (ASCI) in 2010, and in 2018, she was elected to the Association of American Physicians (AAP). In 2019, she was elected Councilor-at-Large of the American Gastroenterological Association (AGA) Governing Board, where she served a three-year term. She also completed a three-year term as Chair of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) in 2022. She is the current President-Elect of the AGA. Upon her election as President in 2024, she will be the fifth woman and first Latina to hold this position. Dr Abreu is a recipient of the 2019 Sherman Prize by the Bruce and Cynthia Sherman Charitable Foundation.

In 2020, Dr Abreu received the Mentoring Award from the Immunology, Microbiology & Inflammatory Bowel Diseases (IMIBD) section of the AGA. She is the 30th alumnus to be inducted into the University of Miami Miller School of Medicine Hall of Fame.

Visit our booth  
**#C2-24**

These events are open to healthcare professionals who attend UEG Week 2023. Takeda-organized and funded symposia during UEG Week 2023. These symposia are not allied with UEG. Copyright © 2023 Takeda Pharmaceutical Company Limited. All rights reserved. August 2023 | VV-MEDMAT-89797

premier supporter of  
**ueg week**





# Gathering intelligence to improve long-term outcomes in ulcerative colitis: new evidence

MONDAY 16 OCTOBER 2023 | 13:00-14:00 CEST | ROOM A2 | ALSO STREAMED LIVE

## Navigating change: the evolution of treatment goals in ulcerative colitis



**FERNANDO MAGRO (CHAIR)**

São João University Hospital, Porto, Portugal

Fernando Magro is a consultant in gastroenterology. He also acts as Director of the Clinical Pharmacology Unit, medical prescription monitor, Pharmacy Committee consultant and coordinator of the Immunomodulator Study Group at the São João University Hospital, Porto, Portugal.

Professor Magro is the President Elect of the Governing Board of the European Crohn's and Colitis Organisation (ECCO), Associate Editor for the United European Gastroenterology Journal and member of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD). Closer to home, he founded and currently serves as board member and Research Head of the Portuguese IBD Study Group (GEDII).

The main focuses of his clinical research center around inflammatory bowel diseases (IBDs) and intestinal epithelial inflammation. Professor Magro's ultimate aim is to improve patients' quality of life through translational research and decision-making processes, supported by strong scientific evidence.

With his colleagues at GEDII and Faculdade de Medicina da Universidade do Porto (FMUP), he has developed numerous studies correlating drug levels to new serum and fecal biomarkers. Professor Magro has published more than 300 manuscripts, with more than 19,000 citations, and was the national coordinator for seven global clinical trials in IBD. He has delivered more than 100 international talks and organized more than 50 national meetings.

## Bridging the gap between histology and clinical practice



**ALESSANDRO ARMUZZI**

Humanitas University, Milan, Italy

Alessandro Armuzzi leads the Inflammatory Bowel Disease (IBD) Center at the Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Humanitas Research Hospital, Milan, Italy. He is also a Professor of Gastroenterology at Humanitas University, Milan.

Professor Armuzzi trained at the University of Bologna, Catholic University of Rome, and completed advanced research and clinical training in IBD at the John Radcliffe Hospital, Oxford University Hospitals, UK.

Professor Armuzzi's research interests focus on the design of both real-life trials and observational studies in IBD, clinical/biological prediction and outcomes in IBD and other immune-mediated diseases, diagnostic modalities to assess disease activity in IBD, and advanced IBD therapies. He has authored many peer-reviewed publications on these topics.

Professor Armuzzi served as a member of several gastroenterology associations, including the Scientific Committee of the Italian Society of Gastroenterology (SIGE, Scientific Committee), the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD, Chair from 2018 to 2019) and has fulfilled multiple roles within the European Crohn's and Colitis Organisation (ECCO) including Chair of the Clinical Research Committee (ClinCom) between 2015 and 2017. He is currently the General Secretary of ECCO; a post he has held since 2021.



**BRUCE SANDS**

Icahn School of Medicine at Mount Sinai, New York, NY, USA

Bruce Sands is the Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York. Dr Sands is an expert in the management of inflammatory bowel disease (IBD). He was awarded his BA and MD from Boston University, MA, and trained in internal medicine at the Hospital of the University of Pennsylvania, PA.

Dr Sands joined the faculty of Harvard Medical School and served as Acting Chief of the Gastrointestinal Unit at Massachusetts General Hospital before moving to Mount Sinai in 2010 as Chief of the Dr. Henry D. Janowitz Division of Gastroenterology. His clinical research concerns both IBD epidemiology and new therapeutics. During his clinical research, Dr Sands has published nearly 300 original manuscripts in leading journals. Notably, he was the lead investigator of the landmark studies ACCENT II, UNIFI, VARSITY, and SEAVUE.

Dr Sands is a past chair of the Clinical Research Alliance (CRA) of the Crohn's & Colitis Foundation of America and has served as Chair of the Immunology, Microbiology and Inflammatory Bowel Disease Section of the American Gastroenterological Association (AGA). Additionally, he was Chair of the International Organization for the Study of IBD (IOIBD). In 2016, Dr Sands was awarded the Dr. Henry Janowitz Lifetime Achievement Award from the Crohn's & Colitis Foundation.